Skip to main content
SpringerLink
Log in

Systemische Verlaufsform der juvenilen idiopathischen Arthritis (Morbus Still)

  • Chapter
  • First Online:
Pädiatrische Rheumatologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1502 Accesses

Zusammenfassung

Die systemische juvenilen idiopathische Arthritis (sJIA) wird durch eine Arthritis, remittierendes Fieber sowie ein typisches flüchtiges Exanthem (sogenannter Rash) charakterisiert. Die sJIA gehört zu den seltenen Formen der JIA und wird als autoinflammatorische Systemerkrankung verstanden. Die Voraussetzung für eine erfolgreiche Therapie ist eine frühzeitige Diagnosestellung und kinderrheumatologische Behandlung. Interleukin 1 spielt eine zentrale Rolle in der Pathogenese der sJIA und als therapeutisches Zielmolekül. Die Ziele der Therapie sind die effektive Behandlung der Grunderkrankung durch eine rasche Entzündungskontrolle, die Schmerzbekämpfung, die Vermeidung von Gelenkkontrakturen, Gelenkdestruktionen, und Wachstumsstörung, die Vermeidung der Schädigung innerer Organe und die Gewährleistung einer weitgehend störungsfreien somatischen und psychosozialen Entwicklung der Kinder und Jugendlichen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 229.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Austermann J, Spiekermann C, Roth J (2018) S100 proteins in rheumatic diseases. Nat Rev Rheumatol 14(9):528–541

    Article  CAS  PubMed  Google Scholar 

  • Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 60(7):2102–2112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP (2003) Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 143(4):512–519

    Article  CAS  PubMed  Google Scholar 

  • Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 35(2):343–348

    PubMed  Google Scholar 

  • Benedetti F de, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34(9):1158–1163

    Google Scholar 

  • Benedetti F de, Pignatti P, Gerloni V, Massa M, Sartirana P, Caporali R, Montecucco CM, Corti A, Fantini F, Martini A (1997) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 24(7):1403–1409

    Google Scholar 

  • Benedetti F de, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, Printo and Prcsg (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2385–2395

    Google Scholar 

  • Benedetti F de, Brogan P, Grom A, Quartier P, Schneider R, Jacqmin P, Ballabio M, de Min C (2019) Emapalumab, an interferon gamma (IFN-Y)-blocking monoclonal antibody, in patientswith macrophage activation syndrome (MAS)complicating systemic juvenile idiopathic arthritis (SJIA). Ann Rheum Dis 78:178

    Google Scholar 

  • Berthold E, Mansson B, Kahn R (2019) Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther 21(1):218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702

    CAS  PubMed  Google Scholar 

  • Cader MZ, Boroviak K, Zhang Q, Assadi G, Kempster SL, Sewell GW, Saveljeva S, Ashcroft JW, Clare S, Mukhopadhyay S, Brown KP, Tschurtschenthaler M, Raine T, Doe B, Chilvers ER, Griffin JL, Kaneider NC, Floto RA, D’Amato M, Bradley A, Wakelam MJ, Dougan G, Kaser A (2016) C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol 17(9):1046–1056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cleary AG, Murphy HD, Davidson JE (2003) Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child 88(3):192–196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fassl SK, Austermann J, Papantonopoulou O, Riemenschneider M, Xue J, Bertheloot D, Freise N, Spiekermann C, Witten A, Viemann D, Kirschnek S, Stoll M, Latz E, Schultze JL, Roth J, Vogl T (2015) Transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8. J Immunol 194(2):575–583

    Article  CAS  PubMed  Google Scholar 

  • Feldmann R, Weglage J, Roth J, Foell D, Frosch M (2005) Systemic juvenile rheumatoid arthritis: cognitive function and social adjustment. Ann Neurol 58(4):605–609

    Article  PubMed  Google Scholar 

  • Frosch M, Roth J (2008) New insights in systemic juvenile idiopathic arthritis – from pathophysiology to treatment. Rheumatology (Oxford) 47(2):121–125

    Article  CAS  Google Scholar 

  • Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, Foell D, Sorg C, Sunderkotter C, Roth J (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48(9):2622–2626

    Article  CAS  PubMed  Google Scholar 

  • Frosch M, Metze D, Foell D, Vogl T, Sorg C, Sunderkotter C, Roth J (2005) Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 14(4):259–265

    Article  PubMed  Google Scholar 

  • Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(3):883–891

    Article  CAS  PubMed  Google Scholar 

  • Gare BA, Fasth A (1992) Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 90(6):950–958

    Article  CAS  PubMed  Google Scholar 

  • GKJR (2019) S2k Leitlinie Therapie der Juvenilen Idiopathischen Arthritis, 3. Aufl. https://www.awmf.org/leitlinien/detail/ll/027-020.html. Zugegriffen am 10.02.2021

  • Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, R. Nordic Study Group of Pediatric (2020) Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken) 72(4):507–516

    Article  Google Scholar 

  • Grom AA (2004) Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 50(3):689–698

    Article  PubMed  Google Scholar 

  • Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H (2006) Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. Clin Exp Rheumatol 24(5):499–507

    CAS  PubMed  Google Scholar 

  • Harvey AR, Pippard MJ, Ansell BM (1987) Microcytic anaemia in juvenile chronic arthritis. Scand J Rheumatol 16(1):53–59

    CAS  PubMed  Google Scholar 

  • Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL (2010) Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 62(2):599–608

    PubMed  Google Scholar 

  • Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Monkemoller K, Neudorf U, Weissbarth-Riedel E, Wittkowski H, Horneff G, Foell D, P.-K. S. p. collaborators (2018) Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 16(1):7

    Article  PubMed  PubMed Central  Google Scholar 

  • Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980

    Article  CAS  PubMed  Google Scholar 

  • Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP (2017) Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 19(1):256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, Gardner-Medwin J, Wedderburn LR, Chieng A, Davidson J, Thomson W (2010) Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 49(1):116–122

    Article  Google Scholar 

  • Jager W de, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66(5):589–598

    Google Scholar 

  • Jager W de, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ (2009) Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(9):2782–2793

    Google Scholar 

  • Jager W de, Canna SW, Liu Y, Goldbach-Mansky R (2015) Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 33:823–874

    Google Scholar 

  • Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, Rabinovich E, Riebschleger M, Anton J, Blier PR, Gerloni V, Hazen MM, Kessler E, Onel K, Passo MH, Rennebohm RM, Wallace CA, Woo P, Wulffraat N, I. Childhood Arthritis Rheumatology Research Alliance Carra Net (2013) Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 65(5):745–752

    Article  CAS  Google Scholar 

  • Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K (2017) Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. Semin Arthritis Rheum 47(2):269–275

    Article  PubMed  Google Scholar 

  • Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N, O. Pediatric Rheumatology International Trials (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 46(2):190–197

    Article  PubMed  Google Scholar 

  • Mellins ED, Macaubas C, Grom AA (2011) Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7(7):416–426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129(5):750–754

    Article  CAS  PubMed  Google Scholar 

  • Nigrovic PA (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 66(6):1405–1413

    Article  CAS  PubMed  Google Scholar 

  • Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555

    Article  CAS  PubMed  Google Scholar 

  • Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M, R. Nordic Study Group of Pediatric (2011) Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 63(9):2809–2818

    Article  PubMed  Google Scholar 

  • Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chedeville G, Chetaille AL, Saint-Cyr C, Cabral DA, Spiegel LR, Schneider R, Lang B, Huber AM, Dancey P, Silverman E, Rosenberg AM, Cameron B, Johnson N, Dorval J, Scuccimarri R, Campillo S, Petty RE, Duffy KN, Boire G, Haddad E, Houghton K, Laxer R, Turvey SE, Miettunen P, Gross K, Guzman J, Benseler S, Feldman BM, Espinosa V, Yeung RS, Tucker L (2010) Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken) 62(4):527–536

    Article  Google Scholar 

  • Okamura N, Tamba M, Liao HJ, Onoe S, Sugita Y, Dacheux F, Dacheux JL (1995) Cloning of complementary DNA encoding a 135-kilodalton protein secreted from porcine corpus epididymis and its identification as an epididymis-specific alpha-mannosidase. Mol Reprod Dev 42(2):141–148

    Article  CAS  PubMed  Google Scholar 

  • Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Ozen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcon-Riquelme ME, Docampo E, Estivill X, Gul A, P. British Society of, G. Adolescent Rheumatology Study, G. Childhood Arthritis Prospective Study, J. I. A. I. Randomized Placebo Phase Study of Rilonacept in s, G. Sparks-Childhood Arthritis Response to Medication Study, J. I. A. G. Biologically Based Outcome Predictors in, de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P, C. International Childhood Arthritis Genetics (2015) HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 112(52):15970–15975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Ozen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcon-Riquelme ME, Docampo E, Estivill X, Gul A, P. British Society of, I. C. o. N. D. P. w. J. I. A. S. G. C. A. P. S. G. R. P. P. S. o. R. i. s. I. S.-. Adolescent Rheumatology Study Group, Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W (2017) Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis 76(5):906–913

    Article  CAS  PubMed  Google Scholar 

  • Pardeo M, Bracaglia C, de Benedetti F (2017) Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies. Best Pract Res Clin Rheumatol 31(4):505–516

    Article  PubMed  Google Scholar 

  • Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pelkonen P, Swanljung K, Siimes MA (1986) Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand 75(1):64–68

    Article  CAS  PubMed  Google Scholar 

  • Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392

    PubMed  Google Scholar 

  • Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377(9783):2138–2149

    Article  PubMed  Google Scholar 

  • Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Kone-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debre M, Landais P, Prieur AM (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093–1101

    Article  CAS  PubMed  Google Scholar 

  • Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–754

    Article  CAS  PubMed  Google Scholar 

  • Ravelli A (2002) Macrophage activation syndrome. Curr Opin Rheumatol 14(5):548–552

    Article  CAS  PubMed  Google Scholar 

  • Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767–778

    Article  CAS  PubMed  Google Scholar 

  • Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK, American Collge of Rheumatology (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65(10):2499–2512

    Article  PubMed  PubMed Central  Google Scholar 

  • Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, Pediatric Rheumatology International Trials Organization (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201

    Article  CAS  PubMed  Google Scholar 

  • Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, Printo and Prcsg (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2396–2406

    Article  CAS  PubMed  Google Scholar 

  • Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group (2018) Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 77(12):1710–1719

    Article  CAS  PubMed  Google Scholar 

  • Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, De A, de Benedetti F, Ferguson I, Fishman MP, Goodman SI, Graham TB, Grom AA, Haines K, Hazen M, Henderson LA, Ho A, Ibarra M, Inman CJ, Jerath R, Khawaja K, Kingsbury DJ, Klein-Gitelman M, Lai K, Lapidus S, Lin C, Lin J, Liptzin DR, Milojevic D, Mombourquette J, Onel K, Ozen S, Perez M, Phillippi K, Prahalad S, Radhakrishna S, Reinhardt A, Riskalla M, Rosenwasser N, Roth J, Schneider R, Schonenberg-Meinema D, Shenoi S, Smith JA, Sonmez HE, Stoll ML, Towe C, Vargas SO, Vehe RK, Young LR, Yang J, Desai T, Balise R, Lu Y, Tian L, Bejerano G, Davis MM, Khatri P, Mellins ED, Childhood Arthritis and Rheumatology Research Alliance Registry Investigators (2019) Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 78(12):1722–1731

    Article  CAS  PubMed  Google Scholar 

  • Saper VE, Chen G, Khatri P, Mellins ED (2020) Response to: ‚effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report‘ by Bader-Meunier et al. Ann Rheum Dis

    Google Scholar 

  • Sengler C, Klotsche J, Niewerth M, Liedmann I, Foll D, Heiligenhaus A, Ganser G, Horneff G, Haas JP, Minden K (2015) The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open 1(1):e000074

    Article  PubMed  PubMed Central  Google Scholar 

  • Simon D, Fernando C, Czernichow P, Prieur AM (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 29(6):1296–1300

    CAS  PubMed  Google Scholar 

  • Speckmaier M, Findeisen J, Woo P, Hall A, Sills JA, Price T, Hollingworth P, Craft A, Ansell BM (1989) Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 7(6):647–650

    CAS  PubMed  Google Scholar 

  • Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40(11):1285–1292

    Article  CAS  Google Scholar 

  • Still GF (1897) On a form of chronic joint disease in children. Med Chir Trans 80:47–60 49

    Google Scholar 

  • Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P (1996) Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 23(11):1975–1980

    CAS  PubMed  Google Scholar 

  • Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, Verwoerd A, Foell D, Vogl T, Roth J, Leliefeld PHC, van Loosdregt J, Koenderman L, Vastert SJ, de Roock S (2018) Reversal of sepsis-like features of neutrophils by interleukin-1 blockade in patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol 70(6):943–956

    Article  CAS  PubMed  Google Scholar 

  • Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ (2019) Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol 71(7):1163–1173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vandenhaute J, Wouters CH, Matthys P (2019) Natural killer cells in systemic autoinflammatory diseases: a focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome. Front Immunol 10:3089

    Article  CAS  PubMed  Google Scholar 

  • Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, Franck-Larsson K, Fautrel B, de Benedetti F (2019) Anakinra in children and adults with Still’s disease. Rheumatology (Oxford) 58(Suppl 6):vi9–vi22

    Article  Google Scholar 

  • Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31(10):2071–2075

    PubMed  Google Scholar 

  • Vogl T, Stratis A, Wixler V, Voller T, Thurainayagam S, Jorch SK, Zenker S, Dreiling A, Chakraborty D, Frohling M, Paruzel P, Wehmeyer C, Hermann S, Papantonopoulou O, Geyer C, Loser K, Schafers M, Ludwig S, Stoll M, Leanderson T, Schultze JL, Konig S, Pap T, Roth J (2018) Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Invest 128(5):1852–1866

    Article  PubMed  PubMed Central  Google Scholar 

  • Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA, Al-Younes B, Shinwari J, Al-Mohanna FA, Meyer BF, Al-Mayouf S (2015) Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 67(1):288–295

    Article  CAS  PubMed  Google Scholar 

  • Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Fruhwald MC, Dassmann S, Pham TH, Roth J, Foell D (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Woo P (1994) Amyloidosis in children. Baillieres Clin Rheumatol 8(3):691–697

    Article  CAS  PubMed  Google Scholar 

  • Woo P, Wedderburn LR (1998) Juvenile chronic arthritis. Lancet 351(9107):969–973

    Article  CAS  PubMed  Google Scholar 

  • Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43(8):1849–1857

    Article  CAS  PubMed  Google Scholar 

  • Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430

    CAS  PubMed  Google Scholar 

  • Yasin S, Schulert GS (2018) Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol 30(5):514–520

    Article  CAS  PubMed  Google Scholar 

  • Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998–1006

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Immunologie, Westfälische-Wilhelms-Universität Münster, Münster, Deutschland

    Johannes Roth

  2. Rheumatologie/Immunologische Ambulanz, Universitätsklinikum Essen, Klinik für Kinderheilkunde III, Essen, Deutschland

    Dirk Holzinger

  3. Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin und Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Deutschland

    Kirsten Minden

Authors
  1. Johannes Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Holzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirsten Minden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Roth .

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  2. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Günther Dannecker

  3. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roth, J., Holzinger, D., Minden, K. (2022). Systemische Verlaufsform der juvenilen idiopathischen Arthritis (Morbus Still). In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60410-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-60410-6_26

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-60409-0

  • Online ISBN: 978-3-662-60410-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation